Payer Intelligence Briefing · Market Access & Reimbursement · GLP-1 GLP-1 Payer Insights 2026 Strategic Briefing: A Cross-System Pricing & Reimbursement Analysis of UK and US Market Access A like-for-like comparison of how the UK NICE-NHS and US Medicaid MCO systems answer the same strategic questions on GLP-1 reimbursement, built on real-world qualitative interviews with…
By Ajay Karandikar, Founder & CEO, Omnitheia | 8 minute read There is a conversation happening across life sciences right now. It goes roughly like this: “We tried AI. The outputs looked convincing, but we couldn’t verify them. We presented insights to leadership and were challenged on accuracy and sources. We couldn’t find it.” That…
Reading Time: 2 minutes In the high-stakes environment of pharmaceutical licensing, winning a successful bid requires a valuation that is both aggressive and defensible. Our recent case study focuses on clinical and commercial valuation of “Drug X“, a blinded Phase 2 KRAS inhibitor. Omnitheia’s strategic framework is designed to provide a comprehensive valuation for assets…
Omnitheia enhances your Target Product Profile with real-world evidence, integrating curated data and stakeholder insights to maximize clinical and commercial potential.
Omnitheia Confidence Score ensures Life Sciences analyses are accurate, verified, and risk-free; giving leaders certainty in high-stakes decisions.